491
492
493
494
495
496
497
498
499
500
Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, J.E.M., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., ten Berg, J. M., van 't Hof, A. W. J., Hermanides, R. S.
Veröffentlicht in: Selvarajah , A , Tavenier , A H , Bor , W L , Houben , J E M , Rasoul , S , Kaplan , E , Teeuwen , K , Hofma , S H , Lipsic , E , Amoroso , G , van Leeuwen , M A H , ten Berg , J M , van 't Hof , A W J & Hermanides , R S 2021 , ' Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention : rationale of the Dutch Cangrelor Registry ' , BMC Cardiovascular Disorders , vol. 21 , no. 1 , 292 . https://doi.org/10.1186/s12872-021-02093-4;
2021
Veröffentlicht in: Selvarajah , A , Tavenier , A H , Bor , W L , Houben , J E M , Rasoul , S , Kaplan , E , Teeuwen , K , Hofma , S H , Lipsic , E , Amoroso , G , van Leeuwen , M A H , ten Berg , J M , van 't Hof , A W J & Hermanides , R S 2021 , ' Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention : rationale of the Dutch Cangrelor Registry ' , BMC Cardiovascular Disorders , vol. 21 , no. 1 , 292 . https://doi.org/10.1186/s12872-021-02093-4;
2021